Multiplexed lung cancer fusion detection without FISH or NGS
The detection of gene translocations in lung cancer samples can reveal actionable molecular targets for therapy. Translocations of ALK, ROS1, RET and more recently NTRK are oncogenic drivers of non-small cell lung cancer (NSCLC). Drugs with high therapeutic efficacy towards the resulting fusion proteins are currently available. However, the low incidence of these translocations and often limited number of tumor cells in a NSCLC biopsy creates a challenge for molecular analysis. Consecutive immunohistochemistry and/or DNA FISH is costly, time consuming and often not feasible. NGS affords multiplexing, but requires a complicated, long workflow and has a high cost per sample. The NanoString nCounter platform enables the detection of up to 800 different transcripts, including ALK, ROS1,RET and NTRK fusion transcripts, and other druggable targets such as METexon 14 skipping. This simple and fast multiplex approach enables the detection of these rare mutations in a single assay in less than 24 hrs while only using 150 ng total RNA. I will discuss our lab’s experience with implementating NanoString profiling for the detection of fusion transcripts in NSCLC.
FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.